More than 150 Companies Adopt Veeva Vault RIM Applications to Streamline Regulatory Processes
February 12 2019 - 12:25PM
Business Wire
Leading organizations are choosing Vault RIM
for a single authoritative source of content and data to improve
regulatory business operations and compliance
Veeva Systems (NYSE:VEEV) today announced increasing numbers of
life sciences companies are adopting applications in Veeva Vault
RIM, the first unified suite of RIM applications on one cloud
platform, to modernize their regulatory processes and systems. More
than 150 companies are implementing Vault RIM applications,
including four of the top 10 largest global pharmaceutical
companies, to streamline submission development and provide greater
visibility across end-to-end processes.
Vault RIM brings together regulatory content and data on a
single platform so teams have one authoritative source for
submission documents, published dossiers, health authority
interactions, and product registrations. With Vault RIM, life
sciences companies can eliminate the need for multiple systems and
manual tracking that slow execution and increase compliance
risk.
The latest addition to the Vault RIM suite of applications,
Veeva Vault Submissions Publishing, is a new approach that brings
together publishing activities with document planning, authoring,
and approval in a single system to streamline the entire submission
development process. This enables customers to significantly speed
regulatory submission preparation and delivery. Melinta
Therapeutics, for example, cut its submission development time in
half and published 100 submissions within the first two months of
using Vault Submissions Publishing.
Vault Submissions Publishing enables a continuous publishing
process to finish publishing steps sooner so validation issues are
identified and fixed faster for greater efficiency and improved
compliance. Continuous publishing eliminates the manual movement of
documents between multiple systems and reduces the number of
document transfers to one – when the dossier is transmitted
directly to the health authority.
“With a continuous publishing model, regulatory teams can
identify any errors and address broken links to source data as the
submission is being built so teams don’t have to go through the
lengthy republishing process over and over,” said Shelly Plapp,
director of regulatory operations at Melinta. “By the time you are
ready to publish, the submission is already quality checked and
correct.”
“Veeva innovation is transforming RIM globally across the life
sciences industry,” said John Lawrie, vice president, Veeva Vault
RIM. “Melinta is a great example of how companies can benefit from
a single unified system that streamlines regulatory activities to
speed submissions.”
Veeva Vault RIM Suite includes Vault Registrations, Vault
Submissions, Vault Submissions Publishing, and Vault Submissions
Archive. Vault RIM is part of Veeva Development Cloud, a unified
suite of applications for clinical, regulatory, and quality to help
organizations drive end-to-end business processes across R&D
and manufacturing.
To learn more about how leading life sciences organizations are
modernizing their regulatory processes and systems, visit Veeva at
booth #21 at eRegulatory Summit in Barcelona, Spain, April 8 -
10.
Additional Information
For more on Veeva Vault RIM Suite, visit:
veeva.com/eu/RIMConnect with Veeva on LinkedIn:
linkedin.com/company/veeva-systemsFollow @veeva_eu on Twitter:
twitter.com/veeva_euLike Veeva on Facebook:
facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the
global life sciences industry. Committed to innovation, product
excellence, and customer success, Veeva has more than 675
customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices throughout North America, Europe,
Asia, and Latin America. For more information, visit
veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva’s products and services,
the results from use of Veeva’s products and services, and general
business conditions, particularly in the life sciences industry.
Any forward-looking statements contained in this press release are
based upon Veeva’s historical performance and its current plans,
estimates, and expectations, and are not a representation that such
plans, estimates, or expectations will be achieved. These
forward-looking statements represent Veeva’s expectations as of the
date of this press announcement. Subsequent events may cause these
expectations to change, and Veeva disclaims any obligation to
update the forward-looking statements in the future. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual results to differ
materially. Additional risks and uncertainties that could affect
Veeva’s financial results are included under the captions, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on
Form 10-Q for the period ended October 31, 2018. This is
available on the company’s website at veeva.com under the Investors
section and on the SEC’s website at sec.gov. Further information on
potential risks that could affect actual results will be included
in other filings Veeva makes with the SEC from time to time.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the
Veeva logo are trademarks of Veeva Systems Inc. Veeva Systems Inc.
owns other registered and unregistered trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190212005741/en/
Roger VillarealVeeva
Systems925-264-8885roger.villareal@veeva.com
Kiran MayVeeva Systems+44-796-643-2912kiran.may@veeva.com
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Apr 2023 to Apr 2024